18th World Congress Agenda: Day 1 – Tuesday 10th October 2017

Plenary Session ROOM: RUBI/ZAFIR 08:50 Chair’s opening remarks Dr Gregory Poland, Director, Mayo Clinic 09:00 Opening plenary discussion: Creating a new strategy - How does the current global outbreak response system need to change? Moderator: Dr Gregory Poland, Director, Mayo Clinic Speakers: Dr Marie-Paule Kieny, Former Assistant Director-General - Health Systems and Innovation, WHO Richard Hatchett, CEO, CEPI Prof Helen Rees, Chair and Executive Director, Wits Reproductive Health and HIV Institute 10:00 Maternal immunisation: Where do we stand and how do we use , antivirals and – What’s the strategy? Francesca Ceddia, VP, Head Global Medical Affairs Vaccines, GSK Vaccines 10:30 Break the ice with your peers and exchange business cards in the conference room 10:40 Morning Networking Break Therapeutic Vaccines Track Respiratory Vaccines Track ONE HEALTH with

ROOM: RUBI ROOM: ZAFIR ROOM: ROSSINI 11:40 Chair’s opening remarks Chair’s opening remarks Chair’s opening remarks Dr Emmett V. Schmidt, Exec Director, Clinical Dr Gregory Poland, Director, Mayo Clinic Nathalie Garcon, CEO/CSO, BIOASTER Research, Merck Research Laboratories - Oncology Therapeutic & Immunotherapy Vaccines Influenza Vaccines Discovery and Drivers for Emerging Diseases 11:45 Why haven't Alzheimer's vaccines succeeded yet? Clinical development of a nasal inactivated influenza Bringing together experts in human and animal health Professor Nikolai Petrovsky, Flinders University vaccine to create new platforms and technologies that will School of Medicine & Chairman of Vaxine Pty Dr Anna-Karin Maltais, CSO, Eurocine Vaccines facilitate a fast, coordinated, and practical response to new infectious diseases as soon as they emerge 12:15 Delivering precision immunotherapy - Progress and potential hurdles for development of a Dr Jean-Christophe Audonnet, Senior Director, Reprogramming dendritic cells to target patient universal flu vaccine Research Strategy and Key Alliances, Bio R&D, Merial specific Dr Jerald Sadoff, Senior Advisor Vaccine and Coordinator, ZAPI Jeff Abbey, CEO, Argos Therapeutics Development, Janssen Infectious Diseases and Dr Bart Haagmans, Working Group Leader, Department Vaccines of Viroscience, Erasmus M.C., & Co-coordinator, ZAPI

12:45 Targeted vaccination against the bevacizumab The challenge of childhood influenza vaccination in Virus discovery – New kids on the block with pandemic binding site on VEGF using 3D-structured peptides Europe potential elicits efficient antitumor activity Dr Ruprecht Schmidt-Ott, European Director for Prof Albert Osterhaus, Director Research Center for Dr Peter Timmerman, CSO, Pepscan Therapeutics Scientific Affairs & Public Health, GSK Vaccines Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover

13:15 Networking Lunch & Poster Session 14:45 A pan-HLA predictor of processing and Assays used for vaccine efficacy studies and correlates Innovative mRNA vaccines – From proof of concept to presentation to the cell surface improves the of protection for influenza vaccines evaluation product development, Rabies as an example identification of clinically relevant neoantigens Prof Emanuele Montomoli, Professor at the Public Dr Susanne Rauch, Senior Scientist, CureVac Dr Trevor Clancy, Co-Founder and Chief Scientific Health University of Siena & CSO, VisMederi Officer, OncoImmunity

15:00 Mucosal and systemic immune responses to influenza following oral tablet delivery Dr Sean Tucker, CSO, Vaxart

15:15 Using DNA vaccine based technology to prevent RSV Vaccines Use of vaccination in animals for total epizootic disease potentially life threatening allergies Prepare Trial: A global, multi-season, Ph 3 trial to eradication and anti-microbial resistance control Salim Mujais, SVP, Therapeutic Area Head evaluate the protective efficacy of the RSV F Dr Joseph Domenech, Consultant, ex World Animal Immunology, Transplant, Infectious Disease, CNS nanoparticle vaccine in infants using maternal Health Organization (OIE) Chargé de Mission and FAO and Pain, Astellas Pharma immunization Head of Animal Head Service Dr Gregory Glenn MD, President, Research and Development, Novavax 15:45 Data supporting the value of check point inhibitors, Update on the development of the recombinant RSV Nanovaccines: A new platform technology for AMPLIVANT SLP conjugates and neoantigens in vaccine candidate MVA-BN® RSV immunization against avian infections that impact combinational immunotherapy against HPV Dr Nathaly Samy, Senior Vice President Clinical human health Development, Bavarian Nordic Dr Adel M. Talaat, Prof of Microbiology, University of Willem-Jan Krebber, COO, ISA pharmaceuticals Wisconsin-Madison

16:15 Afternoon Networking Break 16:45 The rationale of combining biomarkers and Landscape analysis of RSV vaccine development and New insight and the challenges associated with the checkpoint inhibitors with vaccines and oncolytics future implications prevention and control of Rift Valley fever Dr Angus Dalgleish, Foundation Chair in Clinical Dr Marta Nunes, Respiratory and Meningeal Dr Osama Ahmed Hassan Ahmed, Epidemiologist, Center Oncology & Research Director, St George's Pathogens Research Unit, University of for Global Health, Department of Community Medicine University, London Witwatersrand, Soweto South Africa and Global Health, Oslo University

17:15 Oncolytic viruses as immunotherapy - Establishing Developments and updates on an adjuvanted RSV F Development of proprietary polysaccharide vaccine the legitimacy of oncolytic viruses in therapy RSV Vaccine to protect healthy and high-risk older adjuvants that meet the needs of humans and animals Dr Brian R. Champion, CSO, PsiOxus Therapeutics adults: Building on clinical experience when concerning Influenza, West Nile and other re- Dr Vivek Shinde, MD, MPH, Director, Clinical emerged viruses Development, Novavax Professor Nikolai Petrovsky, Flinders University School of Medicine & Chairman of Vaxine Pty 17:45 Chair closing remarks of day one followed by Drinks Reception @ Fabrica Mortiz Barcelona – Coaches leave from 6pm for a 5 min drive Hosted by:

Day 2 – Wednesday 11th October 2017

ROOM: RUBI/ ZAFIR ROOM: ROSSINI ROOM: DIAMANT 09:00 Chair’s opening remarks Chair’s opening remarks Chair’s opening remarks Dr Gregory Poland, Director, Mayo Clinic Nathalie Garcon, CEO/CSO, BIOASTER Prof Farzin Farzaneh, Professor of Molecular Medicine, King's College London & Honorary Consultant in Specialist Medicine, King’s College Hospital NHS Trust 09:10 Plenary discussion: Where is the global vaccine industry Control, Prevention & Breakthrough Trends Exciting Immune-Manipulation Approaches shifting to for new collaborations? Perspectives from Changing Veterinary Vaccine Landscapes emerging markets and Asia Prevention of food borne diseases through Development of TCR based adoptive therapies: Dr Suresh Beri, Additional Director, Conjugate Vaccines, vaccination: Challenges and opportunities in the opportunities and challenges Serum Institute of India global poultry industry Dr Kai Pinkernell, Chief Medical Officer and Senior Vice Dr Krishna Ella, Founder and Chairman, Bharat Biotech Dr Dharanesh Gangaiah, Bacteriologist, Molecular President of Medical Affairs, Medigene Dr Michael Makanga, Executive Director, European & Bacteriology and Bacterial Foodborne Illnesses, Developing Countries Clinical Trials Partnership (EDCTP) Elanco 09:40 Dr Jean Lang, Associate Vice President, R&D, NV Disease prevention in relation to animal welfare Combinational immunotherapy in oncology: Increasing Projects Global Health, Partnerships & Funding, Sanofi Rik Koopman, Global Technical Director, MSD the effective targeting of neo-epitopes Pasteur Animal Health Dr Emmett V. Schmidt MD PhD, Executive Director, Yves Leurquin, Head, Vaccines Market Access, Takeda Clinical Research, Merck Research Laboratories - Pharmaceuticals International Bioprocessing, Manufacturing and Innovative New Oncology Technology 10:10 Where are we in polio eradication? What are the Development of a serum free medium for Integrated immune monitoring solutions for preclinical remaining challenges? expansion of BHK-21 cells for vaccine production and clinical development of immunotherapeutics Dr Phil Minor, Former Deputy Director, Head of Dr James W. Brooks, R&D Manager, BD Biosciences Dr Marcelle Van Mechelen, Senior Scientific Virology, NIBSC & Member of the WHO Advisory Panel Advisor, Caprion Biosciences Inc. on Biological Standardization 10:40 Morning Networking Break

11:40 - 13:10 2 x Interactive Roundtables: 11:40 to 12:25 (rotation one) and 12:25 to 13:10 (rotation two). If you have not filled out the survey please choose them on the sign-up sheets located outside of the exhibition hall/or ask registration for more ROOM: DIAMANT information. Choose two x 45 min long roundtables for these interactive discussions with like-minded peers in: 11:40 1. Incorporating “passive immunization” 2. The significant role of the 3. Progress on Zika vaccine development

Advanced development of with vaccines – the use of Phage therapies microbiome in disease prevention, Dr Gregory Poland, Director, Mayo Clinic innovative immunotherapeutics: In and mABs

RUBI treatment and therapeutic

: combination and exploiting the Dr Eszter Nagy, Co-Founder, Chief development DART platform Scientific Officer, and Managing Director, Jeff Riley, Synthetic Biologics, Inc. Dr Paul Moore, Vice President- ROOM Arsanis Biosciences GmbH Immunology & Cell Biology, MacroGenics Immune Response and Intradermal delivery of The regulators relationship Trends in mammalian Sponsor/CRO Partnership 4. 5. 6. 7. Biomarkers: B-cell & T-cell analysis therapeutic vaccines – with Challenge Studies; cell culture based vaccines Optimization

benefits and challenges yesterday, today & tomorrow Ron Geven, EU Key Account Marc Hoffman, CMO, Celerion 12:10 Dr Kirsty V Gapp, Global Bruno Speder, Head Clinical Manager, BD Biosciences Bernhard Liegl, VP Global Clinical High-resolution profiling of Business Manager Regulatory Affairs, SGS Life Dr James W. Brooks, R&D Development, Celerion responses to arrays of Transdermal and Sciences Manager, BD Biosciences Susanne Eder-Lingelbach, Head peptides Microneedle Drug Delivery, Dr Adrian Wildfire, Project of Clinical Operations, Valneva ROOM: ZAFIR ROOM: Dr Bradley Garcia, Strategic 3M Director - Infectious Diseases Technology Commercialization & Viral Challenge Unit, SGS Life Leader, Roche Sequencing Sciences Solutions 12:40 Advanced veterinary Developing vaccines to Porcine T lymphocytes Using an autologous 8. 9. 10. 11. Development of active immune therapies: stem cells, emerging diseases and effective – analysis of their response cancer vaccine to enhance therapies and therapeutic monoclonal antibodies and use of animal models after vaccination immunotherapy outcomes and vaccination strategies for bacterial phages for Professor Miles W Carroll, Head Prof Dr Armin Saalmüller, tackle a re-occurring disease haematological malignancies veterinary use of Research, Deputy Director, Institute of Immunology, within companion animals Prof Farzin Farzaneh, Professor of Dr Rosario Bullido, Head of National Infections Service, Department of Dr Patrick Frayssinet, R&D Molecular Medicine, King's College Veterinary Inmunological Public Health England Pathobiology, University of Director, URODELIA

ROOM: ROSSINI ROOM: London & Honorary Consultant in Medicines Assessment Unit, Veterinary Medicine Vienna Specialist Medicine, King’s College AEMPS Hospital NHS Trust 13:10 Networking Lunch & Poster Session

Emerging & Re-emerging Clinical Development in Viral Early Development & Diseases Vaccines Manufacturing ROOM: ROSSINI ROOM: DIAMANT ROOM: RUBI ROOM: ZAFIR ROOM: VIVALDI 14:40 Chair’s opening remarks Chair’s opening remarks Chair’s opening remarks Chair’s opening remarks Improving the anti-tumor Prof Albert Osterhaus, Director Professor Miles W Carroll, Dr Antu Dey, Senior Director, Glen Gifford, Chargé de immune response through Research Center for Emerging Head of Research, Deputy Research & Development, mission, Science and New the use of bi-and trifunctional Infections and Zoonoses (RIZ), Director, National Infections International AIDS Vaccine Technologies Department, OiE antibody-cytokine fusion University of Veterinary Service, Public Health England Initiative (IAVI) proteins Medicine Hannover Dr Dafne Mueller, Group Biopreparedness and Vaccine Clinical Outcomes in Viral New Platforms and Process Emerging and Re-emerging Leader, Institute of Cell Progression Vaccines Development Diseases Biology and Immunology, 14:45 Development of live measles The challenges of clinical Pre- formulation and stability Manufacturing within the University of Stuttgart vaccine vector for new development for emerging studies in different vaccines – veterinary industry – the future emerging pathogens infectious diseases – The key considerations of where it’s going Dr Frédéric Tangy, Director of example of Ebola Dr Florence Arvis, Head of Randolph Seidler, Managing R&D, CNRS, Institut Pasteur Dr Melanie Saville, VP, Head of Formulation Unit, Sanofi Director, Veterinary Research 15:10 Accuracy and prediction in Late Development, Clinical and Centre & VP, Global Head of Medical Affairs, Janssen antibody repertoire analysis BD, Boehringer Ingelheim Dr Sai Reddy, Assistant 15:15 Strain and species-specific The problem with How innovative process Prioritising diseases for which Professor, Department of antibody response in a malaria powering…PhII to PhIII, quo development allows for a novel vaccines could reduce Biosystems Science & vaccine field trial and after vadis? cost-effective rotavirus vaccine antimicrobial use in animals Engineering, Laboratory for flavivirus infection Dr Adrian Wildfire, Project Dr Alfred Luitjens, Director Cell preserving the effectiveness of Systems and Synthetic Dr John Tan, Senior Scientist, Director - Infectious Diseases & Technology, Batavia antibiotics Immunology, ETH Zurich / Technology Innovation, Roche Viral Challenge Unit, SGS Life Biosciences Dr Glen Gifford, Chargé de Swiss Federal Institute of 15:30 Sequencing Solutions Sciences Innovative affinity mission, Science and New Technology chromatography platform for Technologies Department, OiE streamlined purification of vaccines at reduced costs and lower environmental footprint Anne Chevrel, Research and Development Project Manager, Affilogic 15:45 Afternoon Networking Break

16:15 Developing a universal vaccine Use of MAV-VLP platform for Bioengineering bacterial outer The role of omics in veterinary Adjuvant profiling and against emerging mosquito- development of vaccines for membrane vesicles as vaccine vaccinology: Opportunities and systems analysis of vaccine transmitted diseases and infectious diseases and cancer platform challenges induced response to enhance influenza Dr Farshad Guirakhoo, CSO, Dr Ivo Ploemen, Program Dr Artur Summerfield, correlates of protection of Dr Olga Pleguezuelos, CSO & GeoVax, inc. Manager, Intravacc Professor for Veterinary human vaccines 16:30 Project Manager, SEEK MACIVIVA – Developing cold Immunology, Group Head, Dr Ali Harandi, Associate chain independent virosomal Institute of Virology and Professor, Lab head, vaccines Immunology University of Gothenburg Dr Sylvain Fleury, CSO, Mymetics 16:45 From vaccines research to ViroSpot MN assay, a novel Challenges of RSV vaccine African Swine Fever - Dealing Oncolytic Virotherapy: A New launch of Dengvaxia and tool for antigenic development with what is yet to come Cornerstone for Immuno- collaborative efforts to create a characterization of influenza Rob Dekker, CMC Team Lead, Dr Marisa Arias, Technical Oncology Zika vaccine viruses and serology Janssen Infectious Diseases and Director, EU Reference Dr Shruthi Naik PhD, Founder Dr Jean Lang, Associate Vice Dr Carel van Baalen, Director Vaccines Laboratory for African swine and VP, Comparative 17:00 President, R&D, NV Projects R&D, Viroclinics Biosciences Interactive panel: Accelerated fever, Instituto Nacional de Oncology, Vyriad & Global Health, Partnerships & development of vaccine Investigación y Tecnología Department of Molecular Funding, Sanofi Pasteur products to human clinical Agraria y Alimentaria (INIA- Medicine, Mayo Clinic trials – Successes and CISA) 17.15 Preventing the pandemic Standardization and challenges Q&As with speakers and Q&As with speakers and potential of MERS-CoV: Updates development of assays for Dr Antu Dey, Senior Director, summary followed up by chair summary followed up by chair on research and clinical assessment of influenza Research & Development, closing remarks for Day 2 closing remarks for Day 2 development vaccines correlates of International AIDS Vaccine Dr James Cummings, VP, Clinical protection Initiative (IAVI) Development and Translational Patricia Londono-Hayes, Head Dr Kunal Aggarwal, Head of Medicine, Novavax R&D Initiatives Europe, Sanofi Technical R&D Programs - R&D Center USA, GSK Vaccines Dr Anissa Boumlic-Courtade, Associate Director, Vaccine initiative, Merck Life Sciences Dr Melanie Saville, VP, Head of Late Development, Clinical and Medical Affairs, Janssen 17:45 Chair’s closing remarks followed by Meet & Greet with key speakers in the Exhibition Hall

Day 3 – Thursday 12th October 2017

ROOM: ROSSINI ROOM: DIAMANT New Technology & Discovery Bacterial Vaccines & Anti- Technology Supporting Delivery Emerging and Re-emerging Immune Response and ROOM: RUBI Microbial Resistance & Manufacture Diseases Biomarkers: B-cell & T-cell ROOM: ZAFIR ROOM: VIVALDI analysis 09:00 Chair’s opening remarks Chair’s opening remarks Chair’s opening remarks Chair’s opening remarks Chair’s opening remarks Dr Jeffrey Almond, Former Vice Dr Jan T Poolman, Head Dr Antu Dey, Senior Director, Dr Glen Gifford, Chargé de Dr Sai Reddy, Assis Prof, Dpt of President Discovery Research Bacterial Vaccine Discovery and Research & Development, mission, Science and New Biosystems Science & and Development, Sanofi and Early Development, Janssen International AIDS Vaccine Technologies Department, OiE Engineering, Lab for Systems Visiting Professor, University of Initiative (IAVI) and Synthetic Immunology, Oxford ETH Zurich/Swiss Federal New Technology Showcases Tuberculosis Symposium Delivery & Manufacture Institute of Technology

09:10 Technology Showcase 1 The role of vaccines to combat Manufacturing capacity Developing veterinary vaccines Immune correlates and Proprietary VLP technology for antibiotic-resistant – planning for live virus vaccines for emerging and re-emerging biomarkers of HIV control after developing safe and efficacious WHO perspective and its impact on product diseases: Gaps and therapeutic HIV vaccination vaccines against enteroviruses Dr Martin Friede, Group Lead, development priorities requirements and treatment interruption and HFMD Transfer of Technology for Dr Scott Shoemaker, Senior Dr Catherine Charreyre, Head Dr Christian Brander, CSO Aelix Dr Zarifah Reed, Medical Health Products, WHO Director, Technical operations, of Research Projects, Merial Therapeutics, ICREA Research Director, Sentinext Therapeutics Takeda’s Global Vaccine Professor, IrsiCaixa A.I.D.S. 09:25 Technology Showcase 2 Technology and Engineering Research Institute Development of a novel vaccine group for Zika that does not bear the inherent risk of inducing ADE Dr Farshad Guirakhoo, CSO, GeoVax, inc.

09:40 Technology Showcase 3 VPM1002: A recombinant BCG Virus safety for viral vaccines A transboundary problem: Immune profiling of anti-drug Using mAbs for targeted as a novel infant and post- and viral vectors Lumpy Skin Disease (LSD) antibodies immunotherapy against exposure adult tuberuclosis Dr Anissa Boumlic-Courtade, Prof Thierry van den Berg, Dr Yariv Wine, Senior Lecturer, bacterial infections vaccine Associate Director, Vaccine Head of the Department on Tel Aviv University Dr Eszter Nagy, Co-Founder, Dr Bernd Eisele, CEO, Vakzine initiative, Merck Life Sciences Animal Infectious Diseases, Chief Scientific Officer, and Projekt Management GmbH CODA-CERVA (Veterinary and Managing Director, Arsanis Agrochemical Research Centre) Biosciences GmbH 09:55 Technology Showcase 4 Structure-based design to tackle vaccine challenges Hans (JPM) Langedijk, Director Subunit Vaccine Design, Janssen Infectious Diseases and Vaccines 10:10 Technology Showcase 5 Prevention of relapse after Abx Viral vectors as vaccine Peste des Petits Ruminants: Developing effective biomarker The next generation of treatment platforms: From State of affairs and the road strategies for advanced clinical conjugate vaccine against Dr Steve Reed, Founder, immunogenicity to impact towards eradication development of Immune Streptococcus pneumoniae President and CEO, IDRI Dr Katie Ewer, Senior Dr Arnaud Bataille, Researcher mobilising monoclonal TCRs infection: A novel Immunologist, Supervisor, in Virology, CIRAD, Deputy against cancer (ImmTACs) bioconjugation approach Jenner Institute, Oxford Head of OIE/FAO Reference Dr David Krige, Head of Dr Amir Faridmoayer, Co- University Laboratory for PPR & Deputy Biomarkers, Immunocore Founder & Vice President Head of EU Reference Limited Discovery, LimmaTech Biologics Laboratory for PPR 10:25 Technology Showcase 6 Novel eVLP candidates to prevent leading causes of congenital birth defects Adam Buckley| Vice President, Business Development, VBI Vaccines 10:40 Morning Networking Break

11:20 Technology Showcase 7 Bacterial Vaccines in Clinical Advances in intradermal drug Application of DIVA vaccines to Harnessing natural bacterial Producing affordable vaccines Development delivery address Bovine Tuberculosis in products to develop pioneering with high productivity Extraintestinal pathogenic E. Dr Yotam Levin, CEO, Cattle and gentle immunotherapy manufacturing technologies coli: Challenges for vaccine NanoPass Technologies Martin Vordermeier, Team treatments Dr Renaud Jacquemart, Director development and clinical Leader, Animal Health and Dr Laura Rosa Brunet, Former Vaccines Process Sciences, progress Henrik Hornsved, Senior Veterinary Laboratories Agency Chief Scientific Officer, Natrix Separations, now part of Dr Jan T Poolman, Head Business Development Immodulon Therapeutics Ltd & MilliporeSigma Bacterial Vaccine Discovery and Manager, West Pharmaceutical Director, Rosa Brunet Early Development, Janssen Services Consulting Ltd 11:40 Technology Showcase 8 Clinical update on the Immuno-oncology, Chronic & Displaying antigens on Virus- Staphylococcus aureus multi- Autoimmune Disease Like-Particles using the plug- antigen vaccine Approaches 11:50 and-display SpyCatcher/SpyTag Dr Stephen Lockhart, Vice Overview of the challenges and The Global Virome Project: ABX196, a promising iNKT technology President and Head of Europe opportunities presented by Bringing an end to pandemics agonist to enhance therapeutic Prof Sumi Biswas, Associate and Asia-Pacific Vaccine Clinical plant-based vaccine Dr Peter Daszak, President, efficacy in oncology Professor, University of Oxford Research and Development manufacturing EcoHealth Alliance Dr Sandrine Crabe, Director (VCRD), Dr Vidadi Yusibov, Executive R&D, ABIVAX Director, Fraunhofer USA 12:00 Technology Showcase 9 The threat GAS as AMR rises From Chikungunya to Zika and and the promise of a vaccine other emerging diseases: rapid Prof David Goldblatt, Professor development based on vector of Vaccinology and platform Immunology, UCL Alexander Kort, Head of Business Processes & Quality, Themis Bioscience 12:20 Afternoon Networking Lunch

ROOM: RUBI/ZAFIR ROOM: ROSSINI ROOM: DIAMANT 13.20 Chair’s opening remarks 13.20 The quest to develop new and improved vaccines 13.20 Engineering 2nd Generation SPEAR™-T Dr Gregory Poland, Director, Mayo Clinic for a range of economically important livestock diseases cells to Overcome TGF-β-Mediated 13:30 Vaccines against antibiotic resistance: The PCV paradigm Dr Richard Mole, Commercialisation Manager, Moredun Prof Ron Dagan, Professor of Paediatrics and Infectious Research Institute Dr Rachel Abbott, Group Leader, Adaptimmune Diseases, Paediatric Infectious Disease Unit, Soroka Regulation & Funding 13:50 University Medical Center 13:50 Interactive Discussion: Fast track licensing - Rapid 13:50 Targeting cancer neoantigens: A registration of novel vaccine platforms panel promising source of immunogens for cancer 14:05 The intestinal microbiome and vaccine effectiveness: Dr Rosario Bullido, Head of Veterinary Immunological immunotherapy Correlation or causality Medicines Assessment Unit Veterinary Medicines Philip Arlen, President and Chief Executive Dr Vanessa Harris, Amsterdam Institute for Global Health Department, AEMPS Officer, Precision Biologics Inc and Development, University of Amsterdam 14:20 Philippe Migraine, Director Regulatory Affairs, 14:20 Enabling boosted anti-tumor immunity by Biologicals New Projects, Merial use of an immuno-oncology-dedicated Jean de Foucald, Senior Bio Regulatory Expert, Ceva adenosine receptor antagonist Dr Reece Marillier, Research Scientist, in vivo Pharmacology Lead, iTeos Therapeutics SA 14:50 14:50 Increasing availability of veterinary medicinal 14:50 Immunoprofiling of tumour-draining products through harmonisation of national regulation lymph nodes: new targets for early intervention 14:55 Plenary Discussion: Vaccines don’t protect, vaccination does! regarding autogeneous farm specific vaccines Dr Tanja De Gruijl, Professor of Translational Moderator: Dr Gregory Poland, Director, Mayo Clinic Jean de Foucald, Senior Bio Regulatory Expert, Ceva Tumor Immunology, V.U. Medisch Centrum Speakers: 15:20 Dr Bart Haagmans, Working Group Leader, Department of 15:20 Harmonisation of registration requirements for Speaker Q&As and chair closing remarks Viroscience, Erasmus M.C., & Co-coordinator, ZAPI veterinary vaccines in East Africa and a regional, time- Dr Norman Begg, Vice President, Head of Scientific Affairs based mutual recognition procedure and Public Health, GSK Vaccines Gillian Cowan, Regulatory Affairs Consultant Prof Susanna Esposito, Professor & Chairperson of ESCMID, University of Perugia, Italy 15:40 Chair’s closing remarks and close of Congress 15:50 Chair’s closing remarks and close of Congress 15:40 Chair’s closing remarks and close of Congress